Navigation Links
Mindray Announces 2008 Fourth Quarter and Full Year Results
Date:3/4/2009

tion, operating results, prospects, and business outlook for fiscal year 2009, customer acceptance of company products, continued R&D spending levels, increased headcounts, growth in the company's business segments and geographies, business execution, growth in medical spending and the factors driving that growth, international expansion, integration of a recently acquired business, introduction of new products, expansion into new geographic markets and localizing our distribution teams, our ability to gain market share, our ability to control costs, and our ability to cross sell products. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained i
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Mindray Medical International Announces Second Quarter 2008 Results
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. Mindray Medical International Announces First Quarter 2008 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. Mindray Medical International Announces Third Quarter 2007 Results
6. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Martek Announces First Quarter 2009 Financial Results
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using ... cell therapy treatments for central nervous system diseases, announced ... the NASDAQ Capital Market under the symbol "CUR." The ... NYSE MKT until the market close on July 10, ... to commence on July 13, 2015. ...
(Date:6/29/2015)... Louis, MO (PRWEB) , ... June 29, 2015 , ... ... 15 – July 16 and for the fourth year in a row, will bring ... what changes are taking place at the intersection of data and technology. The event ...
(Date:6/29/2015)... 29, 2015   For the seventh year running, Across ... their overall digital maturity called the Multichannel Maturometer ... are not maturing fast enough. While it,s true that ... ways overall and customers are increasingly "digital natives", pharma ... customer engagement.  ...
(Date:6/26/2015)... Mass. , June 26, 2015  SeraCare ... vitro diagnostics manufacturers, today announced that it has ... with the National Cancer Institute (NCI), part of ... materials and positive controls for cancer assays.  The ... mix and accurately quantitate control DNA biosynthetics spiked ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Imago MADISON, Wis. Mass storage vendor ... Imago Scientific Instruments to meet the manufacturing challenges ... that Seagate has adopted Imago's LEAP Microscope to provide ... magnetic heads and media. , ,According to the company, ...
... RFID tag MADISON, Wis. A new RFID ... advance showing September 29 to attendees of the its ... is holding its seventh annual E-Business Best Practices ... , ,RFID, which involves tagging products or shipments with ...
... BROOKFIELD, Wis. Fiserv Imagesoft , a ... on Thursday that it has completed enhancement of its ... toward improving the security of image replacement documents (IRDs), ... an original check. , ,The new features of ExchangeGuard ...
Cached Biology Technology:E-business conference to give sneak peek into university RFID laboratory 2
(Date:6/16/2015)... Sweden , June 16, 2015 ... all touch fingerprint sensors in the company,s portfolio from one ... Deliveries are planned to mainly take place during the third ... in Asia . Jörgen Lantto, ... evidence of    the   growing interest from smartphone OEMs ...
(Date:6/15/2015)... According to a new market research report ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... Natural Language Processing Market is expected to grow to ... forecast period 2015-2020. Browse 65 market ...   through 155 P ages and in-depth TOC ...
(Date:6/15/2015)... 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces that its leading payment security ... at Digital Experience! @ NYC June 18th. Digital ... latest innovation in technology to over 300 of the top ... the Metropolitan Pavilion in New York City ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... 2011 GNS Healthcare, Inc. (GNS) is ... lung cancer research with a supercomputing platform that can ... assembled from imaging, genetics, pathology, and other areas. The ... a given treatment. GNS will analyze NCI ...
... TORONTO, Ont., July 12, 2001--Eating nuts every day could ... according to new research from St. Michael,s Hospital and ... online by the journal Diabetes Care , a ... of Toronto Department of Nutritional Sciences; St. Michael,s Hospital ...
... 07/07/11, Clearwater Beach, FL. Research to be presented at ... of Ingestive Behavior (SSIB), the foremost society for research into ... a naturally occurring gut hormone, increases our willingness to pay ... non-food items. Have you ever wondered about why you ...
Cached Biology News:GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients 2GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients 3A 'nutty' solution to type 2 diabetes management 2